Synageva BioPharma Corp. - Product Pipeline Review - 2012

Global Markets Direct, June 2012, Pages: 49

Synageva BioPharma Corp. – Product Pipeline Review – 2012

Summary

Global Market Direct’s pharmaceuticals report, “Synageva BioPharma Corp. - Product Pipeline Review - 2012” provides data on the Synageva BioPharma Corp.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Synageva BioPharma Corp.’s corporate website, SEC filings, investor presentations and featured press releases, both from Synageva BioPharma Corp. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Synageva BioPharma Corp. - Brief Synageva BioPharma Corp. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Synageva BioPharma Corp. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Synageva BioPharma Corp. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Synageva BioPharma Corp.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Synageva BioPharma Corp.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Synageva BioPharma Corp. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Synageva BioPharma Corp.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Synageva BioPharma Corp..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Synageva BioPharma Corp. and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of Synageva BioPharma Corp.; Synageva BioPharma Corp. - Key Therapeutics; Synageva BioPharma Corp. - Pipeline Overview and Promising Molecules; Synageva BioPharma Corp. - News; Synageva BioPharma Corp. - Latest Updates; Synageva BioPharma Corp. - Pipeline; Synageva BioPharma Corp. - Discontinued/Dormant Projects

List of Tables
List of Figures
Synageva BioPharma Corp. Snapshot
Synageva BioPharma Corp. Overview
Key Information
Key Facts
Synageva BioPharma Corp. – Research and Development Overview
Key Therapeutic Areas
Synageva BioPharma Corp. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Synageva BioPharma Corp. – Pipeline Products Glance
Synageva BioPharma Corp. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Synageva BioPharma Corp. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Synageva BioPharma Corp. – Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Synageva BioPharma Corp. – Drug Profiles
AVI-014
Product Description
Mechanism of Action
R&D Progress
SBC-102
Product Description
Mechanism of Action
R&D Progress
SBC-103
Product Description
Mechanism of Action
R&D Progress
SBC-104
Product Description
Mechanism of Action
R&D Progress
SBC-105
Product Description
Mechanism of Action
R&D Progress
SBC-106
Product Description
Mechanism of Action
R&D Progress
SBC-201
Product Description
Mechanism of Action
R&D Progress
SBC-202
Product Description
Mechanism of Action
R&D Progress
Synageva BioPharma Corp. – Pipeline Analysis
Synageva BioPharma Corp. – Pipeline Products by Therapeutic Class
Synageva BioPharma Corp. – Pipeline Products by Route of Administration
Synageva BioPharma Corp. – Pipeline Products By Mechanism of Action
Synageva BioPharma Corp. – Recent Pipeline Updates
Synageva BioPharma Corp. – Locations And Subsidiaries
Head Office
Synageva BioPharma Corp., Recent Developments
Synageva BioPharma Corp.- Press Release
Feb 09, 2012: Synageva BioPharma Announces Encouraging Interim Data From Phase I/II Trial Of SBC-102 At 8th Annual Lysosomal Disease Network World Symposium
Jan 30, 2012: Synageva To Present Phase I/II Clinical Data Of SBC-102 At Lysosomal Disease Network World Symposium
Jan 30, 2012: Synageva To Present Preclinical Data Of SBC-103 At Lysosomal Disease Network World Symposium
Financial Deals Landscape
Synageva BioPharma Corp., Deals Summary
Synageva BioPharma Corp., Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Synageva Biopharma Secures $25 Million In Equity Financing
Synageva BioPharma Secures $45 Million In Financing
Partnerships
Synageva BioPharma Extends Co-Development Agreement With Mitsubishi Tanabe Pharma
Synageva BioPharma Enters Into Research Agreement With Mitsubishi Tanabe Pharma
Morphotek Enters Into An Agreement With Synageva BioPharma
Merger
Synageva BioPharma Completes Merger With Trimeris
Licensing Agreements
AviGenics Enters Into Licensing Agreement With Chromos Molecular Systems
Equity Offering
Synageva BioPharma Files Registration Statement For Public Offering Of Securities For $150 Million
Synageva BioPharma Completes Public Offering Of Common Stock For $90 Million
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Synageva BioPharma Corp., Key Information
Synageva BioPharma Corp., Key Facts
Synageva BioPharma Corp. – Pipeline by Indication, 2012
Synageva BioPharma Corp. – Pipeline by Stage of Development, 2012
Synageva BioPharma Corp. – Monotherapy Products in Pipeline, 2012
Synageva BioPharma Corp. – Phase III, 2012
Synageva BioPharma Corp. – Phase II, 2012
Synageva BioPharma Corp. – Pre-Clinical, 2012
Synageva BioPharma Corp. – Pipeline By Therapeutic Class, 2012
Synageva BioPharma Corp. – Pipeline By Route of Administration, 2012
Synageva BioPharma Corp. – Pipeline Products By Mechanism of Action, 2012
Synageva BioPharma Corp. – Recent Pipeline Updates, 2012
Synageva BioPharma Corp., Deals Summary
Synageva Biopharma Secures $25 Million In Equity Financing
Synageva BioPharma Secures $45 Million In Financing
Synageva BioPharma Extends Co-Development Agreement With Mitsubishi Tanabe Pharma
Synageva BioPharma Enters Into Research Agreement With Mitsubishi Tanabe Pharma
Morphotek Enters Into An Agreement With Synageva BioPharma
Synageva BioPharma Completes Merger With Trimeris
AviGenics Enters Into Licensing Agreement With Chromos Molecular Systems
Synageva BioPharma Files Registration Statement For Public Offering Of Securities For $150 Million
Synageva BioPharma Completes Public Offering Of Common Stock For $90 Million

List of Figures
Synageva BioPharma Corp. – Pipeline by Indication, 2012
Synageva BioPharma Corp. – Pipeline by Stage of Development, 2012
Synageva BioPharma Corp. – Monotherapy Products in Pipeline, 2012
Synageva BioPharma Corp. – Pipeline By Therapeutic Class, 2012
Synageva BioPharma Corp. – Pipeline By Route of Administration, 2012

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• eBay - Strong Execution
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Amazon - Point of Realization in 2013?
• Scientific Games Corporation - Company Analysis
• SunGard - Profile - US
• Progress Software Corp,(PRGS) Profile and Financials, plus E-Commerce & Internet Industry Trends Analysis, Operating Ratio and Financial Averages
• American Greetings Corp,(AM) Profile and Financials, plus E-Commerce & Internet Industry Trends Analysis, Operating Ratio and Financial Averages
• Ixia - Company Analysis